News | February 18, 2023
Lupin receives EIR from USFDA for injectable facility in Nagpur
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
ANSSI Wellness launches Asia’s premier and USA-patented ‘Spinal Decompression Treatment’ center in Nashik
Subscribe To Our Newsletter & Stay Updated
